Stock Split History
Vertex Pharmaceuticals stock split history picture
Vertex Pharmaceuticals (VRTX) has 1 split in our Vertex Pharmaceuticals stock split history database. The split for VRTX took place on August 24, 2000. This was a 2 for 1 split, meaning for each share of VRTX owned pre-split, the shareholder now owned 2 shares. For example, a 1000 share position pre-split, became a 2000 share position following the split.

When a company such as Vertex Pharmaceuticals splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business.

Looking at the Vertex Pharmaceuticals stock split history from start to finish, an original position size of 1000 shares would have turned into 2000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Vertex Pharmaceuticals shares, starting with a $10,000 purchase of VRTX, presented on a split-history-adjusted basis factoring in the complete Vertex Pharmaceuticals stock split history. Vertex Pharmaceuticals split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 12/05/2011
End date: 12/01/2021
Start price/share: $29.60
End price/share: $205.00
Dividends collected/share: $0.00
Total return: 592.57%
Average Annual Total Return: 21.36%
Starting investment: $10,000.00
Ending investment: $69,266.83
Years: 10.00
Vertex Pharmaceuticals develops and commercializes therapies for the treatment of cystic fibrosis (CF) and developing research and development programs in other indications. Co.'s marketed products are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor), which are approved to treat people with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene. Co. is co-developing CTX001, an investigational CRISPR/Cas9-based gene-editing therapy for sickle cell disease and transfusion-dependent beta thalassemia. According to our Vertex Pharmaceuticals stock split history records, Vertex Pharmaceuticals has had 1 split.
Date Ratio
08/24/20002 for 1
VRTX is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

VSCP Split History
VVUS Split History
WAT Split History
WGBS Split History
WOOF Split History
XBIO Split History
XOMA Split History
XRAY Split History
XTNT Split History
ZGNX Split History

Also explore: VRTX shares outstanding history

Email EnvelopeFree VRTX Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Equitable Group Inc. (EQB.CA)
U.S. Well Services (USWS)
InMode Ltd. (INMD)
Sonim Technologies, Inc. (SONM)
AzurRx BioPharma, Inc. (AZRX)
Jaguar Health, Inc. (JAGX)
Microchip Technology Incorporated (MCHP)
ATIF Holdings Limited (ATIF)
Intuitive (ISRG)
Transportation Services, Inc. (PTSI)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »
Funds Holding Vertex Pharmaceuticals
Vertex Pharmaceuticals Insider Buying

Vertex Pharmaceuticals Stock Split History | | Copyright © 2013 - 2021, All Rights Reserved

Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.